The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Certolizumab Pegol Drug Studies Find No New Safety Issues

Certolizumab Pegol Drug Studies Find No New Safety Issues

March 1, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

An analysis of the long-term safety of certolizumab pegol (Cimzia, UCB [CZP]) treatment in adults with rheumatoid arthritis (RA) was recently conducted by Bykerk et al.1 They evaluated data through Nov. 30, 2011, from 10 completed randomized controlled trials (RCT), one open-label, single-dose pharmacokinetic study and seven open-label extension trials.

You Might Also Like
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
  • Certolizumab Pegol Effective for Treating Rheumatoid Arthritis
  • Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
Explore This Issue
March 2015
Also By This Author
  • Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab

Some of these patients have been receiving CZP for up to seven years. All adverse events that occurred from the first day to 84 days after the last dosing day were noted. Any serious infections, malignancies and deaths were evaluated by external experts and validated by an external committee. Event rates (ERs) and incidence rates (IRs) per 100 patient-years (PYs) were reported. Patients had received either 200 mg CZP every two weeks following a loading dose of 400 mg; CZP 400 mg once every four weeks; or 400 mg every two weeks. The drug was administered as either the reconstituted lyophilized powder for injection or in a prefilled syringe for subcutaneous injection. Overall, 4,049 RA patients who received CZP were included in the safety pooling, with a total exposure of 9,277 PYs, and a mean exposure of 2.1 years (range, 0.04–7.6 years).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The most common serious adverse event was pneumonia, occurring more frequently in CZP-treated (vs. placebo-treated) patients. Serious infectious events were lower in CZP-treated patients.

Tuberculosis (TB) was identified in 44 patients, of whom 39 were from high endemic regions. TB screening was conducted following respective national guidelines of the study center before 2007. Subsequently, any patient with a positive purified protein derivative test received prophylaxis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Other opportunistic infections were bronchopulmonary aspergillosis (n=6), esophageal or oral candidiasis (n=9) and disseminated herpes zoster (n=3). In addition, 70 malignancies, including five lymphomas, were identified. Non-melanoma skin cancers were excluded. Infections were the most common reason for study withdrawal.

For patients in the open-label extensions, the rate of serious infections did not increase with prolonged exposure to CZP, which is in line with that reported in the literature for other TNF inhibitors.

In the RCT, there were 11 deaths in CZP-treated patients and one death of a placebo-treated patient.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Across all trials, there were 58 CZP-treated patient deaths, mostly related to cardiovascular events, malignancies and infections. There were no cases of optic neuritis, multiple sclerosis or other demyelinating disorders identified. The overall adverse event incidence rate was 335.9 per 100 PYs for CZP-treated patients vs. 362.3 per 100 PYs for placebo-treated patients. Most adverse events were mild to moderate in intensity. The authors noted that for patients in the open-label extensions, the rate of serious infections did not increase with prolonged exposure to CZP, which is in line with that reported in the literature for other TNF inhibitors. In other words, no new or unexpected safety signals.

Pages: 1 2 3 | Single Page

Filed Under: Drug Updates, Safety Tagged With: Certolizumab Pegol, clazakizumab, drug, FDA, hydrocodone bitartrate, Kaufman, rheumatology, SafetyIssue: March 2015

You Might Also Like:
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
  • Certolizumab Pegol Effective for Treating Rheumatoid Arthritis
  • Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
  • Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)